Disease assessment

CLS has been funded to accelerate the development of its proprietary diagnostic tests based on the patented gene signature technology of the company. This funding confirms the achievement of our Molecular Biomarker technology and confirms completion of development milestones, including in situ detection of specific tumor transcripts in blood and tissues, multiplex gene network deep learning analysis, and predictive tissue/blood assessment. CLS can now offer world class assay development expertise in transcript analysis for biomarker validation and companion diagnostic development for a variety of cancers in partnership with pharmaceutical and biotechnology companies.

Biomarkers for disease assessment & targeted therapeutic development

CLS partners with pharmaceutical and biotechnology companies to validate biomarkers for disease assessment and targeted therapeutic development in cancer and other diseases. These partnerships also provide the foundation for CLS to develop companion diagnostic/prognostic tests in conjunction with partners’ targeted therapeutics. CLS also pursues internal programs to develop proprietary diagnostic tests in specific areas of cancer management.